摘要
免疫治疗的发展使恶性黑色素瘤的患者总体存活率显著改善,特别是免疫检查点抑制剂(immune checkpoint inhibitor,ICIs)的出现推动了黑色素瘤免疫治疗的发展。ICIs主要针对细胞程序性死亡受体-1(programmed cell death receptor-1,PD-1)、程序性死亡配体-1(programmed death-ligand 1,PD-L1)以及细胞毒性T淋巴细胞相关蛋白-4(cytotoxic T-lymphocyte antigen-4,CTLA-4)。随着ICIs在临床上的大规模应用,越来越多的不良反应也逐渐显现,本篇主要概述PD-1单抗或PD-L1单抗在治疗中出现的不良反应类型及特点。
The development of immunotherapy has significantly improved the overall survival rate of patients with malignant melanoma.In particular,the emergence of immune checkpoint inhibitors(ICIs)has promoted the development of immunotherapy for melanoma.Currently,the targets of ICIs are programmed cell death receptor-1(PD-1),programmed cell death-ligand 1(PD-L1),and cytotoxic T-lymphocyte antigen-4(CTLA-4).With the large-scale application of ICIs in clinical practice,more and more adverse reactions have gradually emerged.This article mainly summarizes the types and characteristics of adverse reactions in the treatment of PD-1 antibodies or PD-L1 antibodies.
作者
史锋镝
高全立
SHI Fengdi;GAO Quanli(Department of Immunotherapy,Henan Cancer Hospital(The Affiliated Cancer Hospital of Zhengzhou University),Henan Zhengzhou 450008,China)
出处
《现代肿瘤医学》
CAS
北大核心
2022年第21期4014-4017,共4页
Journal of Modern Oncology
基金
河南省医学科学技术攻关项目(编号:201701030)。
作者简介
史锋镝(1994-),女,河南郑州人,硕士在读,研究方向:肿瘤免疫治疗。E-mail:410982611@qq.com;通讯作者:高全立(1969-),男,河南南阳人,博士,主任医师,研究方向:恶性肿瘤生物免疫治疗及化疗的基础研究及临床研究。E-mail:gaoquanli@aliyun.com。
